213 related articles for article (PubMed ID: 26345573)
21. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Carrier M; Le Gal G; Tay J; Wu C; Lee AY
J Thromb Haemost; 2011 Apr; 9(4):653-63. PubMed ID: 21255254
[TBL] [Abstract][Full Text] [Related]
22. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
[TBL] [Abstract][Full Text] [Related]
23. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
[TBL] [Abstract][Full Text] [Related]
24. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
[TBL] [Abstract][Full Text] [Related]
25. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
26. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
27. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
29. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Cuker A; Husseinzadeh H
J Thromb Thrombolysis; 2015 Apr; 39(3):288-94. PubMed ID: 25669624
[TBL] [Abstract][Full Text] [Related]
30. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Shirley M; Dhillon S
Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
[TBL] [Abstract][Full Text] [Related]
31. Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
Puccetti L; Sammartano V; Calzoni P; Bacchiarri F; Santoni A; Fineschi D; Bocchia M
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):54-58. PubMed ID: 35049019
[TBL] [Abstract][Full Text] [Related]
32. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
33. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
34. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
35. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Zangari M; Tricot G; Polavaram L; Zhan F; Finlayson A; Knight R; Fu T; Weber D; Dimopoulos MA; Niesvizky R; Fink L
J Clin Oncol; 2010 Jan; 28(1):132-5. PubMed ID: 19901114
[TBL] [Abstract][Full Text] [Related]
36. Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Ramacciotti E; Aguiar VCR; Júnior VC; Casella IB; Zerati AE; Fareed J
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):340S-349S. PubMed ID: 30486661
[TBL] [Abstract][Full Text] [Related]
37. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
38. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
39. Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Switzer MP; Wani P; Gosavi S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2015; 13(2):98-104. PubMed ID: 26695421
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E; Galán AM
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):445-58. PubMed ID: 24471416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]